{"id":"dexamethasone-low-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes (anxiety, irritability)"},{"rate":null,"effect":"Increased infection risk"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Gastrointestinal upset"}]},"_chembl":{"chemblId":"CHEMBL1697787","moleculeType":"Small molecule","molecularWeight":"528.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone enters cells and binds to intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene expression. This leads to decreased production of pro-inflammatory cytokines, reduced immune cell activation and proliferation, and suppression of inflammatory responses. Low-dose formulations are used to minimize systemic side effects while maintaining therapeutic benefit.","oneSentence":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:28.637Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus)"},{"name":"Adrenocortical insufficiency"},{"name":"Cerebral edema"},{"name":"Allergic reactions and anaphylaxis"},{"name":"Supportive care in cancer chemotherapy (nausea/vomiting prevention)"}]},"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":"Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms","enrollment":2400},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT00644228","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-07-28","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":525},{"nctId":"NCT07404709","phase":"PHASE1, PHASE2","title":"Study on the Safety and Efficacy of Intratympanic Injection of Small Extracellular Vesicles Derived From Mesenchymal Stem Cells in Severe and Profound Sudden Sensorineural Hearing Loss","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-02-28","conditions":"Sudden Hearing Loss, Extracellular Vesicles","enrollment":9},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT02491632","phase":"PHASE2, PHASE3","title":"Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-08-13","conditions":"Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm","enrollment":90},{"nctId":"NCT02845882","phase":"PHASE3","title":"LBL-2016 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2016-01","conditions":"Lymphoblastic Lymphoma","enrollment":150},{"nctId":"NCT07472816","phase":"PHASE4","title":"The Value of Adding Mini-oral Pulse Steroid Therapy in Preventing Peri-lesional Halo Post Non-cultured Epidermal Cell Suspension (NCES) in Cases With Stable Segmental and Non-acral Vitiligo.","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-15","conditions":"Vitiligo","enrollment":60},{"nctId":"NCT06780202","phase":"PHASE2","title":"Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-27","conditions":"Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury","enrollment":180},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT04328662","phase":"","title":"A Study of Ninlaro in Real World Clinical Practice in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-05-18","conditions":"Multiple Myeloma, Neoplasms, Plasma Cell","enrollment":482},{"nctId":"NCT03589222","phase":"PHASE2","title":"SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2018-07-15","conditions":"Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT05440851","phase":"NA","title":"Platform of Randomized Adaptive Clinical Trials in Critical Illness","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2023-04-30","conditions":"Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High","enrollment":6250},{"nctId":"NCT07099222","phase":"PHASE1, PHASE2","title":"Efficacy of Non-weight Based, Low Dose Dex-Dex Adjuncts in Prolonging Peripheral Nerve Blocks","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2024-10-10","conditions":"Postoperative Pain, Nausea and Vomiting, Postoperative, Dizziness","enrollment":100},{"nctId":"NCT04162210","phase":"PHASE3","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2021-03-24","conditions":"Multiple Myeloma","enrollment":325},{"nctId":"NCT07388069","phase":"PHASE1, PHASE2","title":"Study of TN-001 Topical Eyedrops for Keratoconus","status":"ENROLLING_BY_INVITATION","sponsor":"TheiaNova Ltd.","startDate":"2025-12-23","conditions":"Keratoconus","enrollment":20},{"nctId":"NCT06212336","phase":"PHASE2, PHASE3","title":"ISTH/ANRS 0409s INTEGRATE Lassa Fever Study","status":"RECRUITING","sponsor":"Irrua Specialist Teaching Hospital","startDate":"2025-05-02","conditions":"Lassa Fever","enrollment":1755},{"nctId":"NCT04414475","phase":"PHASE2","title":"A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-07-01","conditions":"Multiple Myeloma, Refractory","enrollment":127},{"nctId":"NCT03020030","phase":"PHASE3","title":"Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-03-03","conditions":"Acute Lymphoblastic Leukemia, Pediatric","enrollment":560},{"nctId":"NCT02969837","phase":"PHASE2","title":"Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-07-10","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT07213375","phase":"PHASE2, PHASE3","title":"High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-09-01","conditions":"Analgetic, Lung Cancer (NSCLC), Video Assisted Thoracic Surgery (VATS)","enrollment":80},{"nctId":"NCT06042725","phase":"PHASE1","title":"MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-04","conditions":"Multiple Myeloma","enrollment":100},{"nctId":"NCT02343042","phase":"PHASE1, PHASE2","title":"Selinexor and Backbone Treatments of Multiple Myeloma Patients","status":"RECRUITING","sponsor":"Karyopharm Therapeutics Inc","startDate":"2015-10","conditions":"Multiple Myeloma","enrollment":300},{"nctId":"NCT06387121","phase":"PHASE2","title":"Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-04-02","conditions":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","enrollment":53},{"nctId":"NCT07169890","phase":"NA","title":"Clinical Insights Into Dextrose Phonophoresis on Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"MTI University","startDate":"2025-11-01","conditions":"Acne Vulgaris","enrollment":115},{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT00098475","phase":"PHASE3","title":"Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-11-03","conditions":"DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma","enrollment":452},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT05911321","phase":"PHASE2","title":"Isa-Pom-Dex in Elderly/Frail Subjects With RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2023-12-05","conditions":"Multiple Myeloma, Relapse, Refractory","enrollment":6},{"nctId":"NCT07014462","phase":"PHASE1","title":"A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML","status":"ENROLLING_BY_INVITATION","sponsor":"University of Vermont","startDate":"2025-09-01","conditions":"AML - Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT03500445","phase":"PHASE2","title":"Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-02-13","conditions":"Myeloma, Multiple Myeloma","enrollment":75},{"nctId":"NCT07039877","phase":"PHASE2","title":"Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients","status":"RECRUITING","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2025-01-02","conditions":"Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL","enrollment":12},{"nctId":"NCT04855136","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":21},{"nctId":"NCT04545242","phase":"PHASE4","title":"Efficacy of DEXamethasone in Patients With Acute Hypoxemic REspiratory Failure Caused by INfEctions","status":"RECRUITING","sponsor":"Dr. Negrin University Hospital","startDate":"2021-07-06","conditions":"Acute Hypoxemic Respiratory Failure","enrollment":980},{"nctId":"NCT06882057","phase":"PHASE2, PHASE3","title":"Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-03-03","conditions":"Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)","enrollment":3000},{"nctId":"NCT06023641","phase":"PHASE2","title":"Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2024-03-13","conditions":"Rhabdomyosarcoma","enrollment":135},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT00734877","phase":"PHASE3","title":"UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2008-07","conditions":"Multiple Myeloma","enrollment":382},{"nctId":"NCT06087653","phase":"PHASE1, PHASE2","title":"Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)","status":"RECRUITING","sponsor":"Starton Therapeutics, Inc","startDate":"2023-10-02","conditions":"Multiple Myeloma","enrollment":24},{"nctId":"NCT01816971","phase":"PHASE2","title":"Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2013-01","conditions":"Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma","enrollment":76},{"nctId":"NCT01946477","phase":"PHASE2","title":"Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting","status":"COMPLETED","sponsor":"Celgene","startDate":"2014-05-29","conditions":"Multiple Myeloma","enrollment":186},{"nctId":"NCT05136560","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Early Administration of Dexamethasone in High-risk Sepsis","status":"RECRUITING","sponsor":"CHA University","startDate":"2021-01-15","conditions":"Sepsis","enrollment":102},{"nctId":"NCT05608837","phase":"PHASE2","title":"Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema","status":"ACTIVE_NOT_RECRUITING","sponsor":"Quan Dong Nguyen","startDate":"2023-05-26","conditions":"Uveitis Related Cystoid Macular Edema, Cystoid Macular Edema, Postoperative","enrollment":28},{"nctId":"NCT04892264","phase":"PHASE1","title":"Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-06-03","conditions":"Plasma Cell Myeloma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT06974669","phase":"NA","title":"The Value of Using Mini-oral Pulse Steroid Therapy Along With Non Cultured Epidermal Cell Suspension (NCES) in Stable Resistant Vitiligo","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-05-12","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT03107182","phase":"PHASE2","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2017-06-27","conditions":"HPV-Related Squamous Cell Carcinoma, HNSCC","enrollment":72},{"nctId":"NCT00408005","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2007-01-30","conditions":"T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma","enrollment":1895},{"nctId":"NCT04131309","phase":"PHASE2","title":"A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Stichting European Myeloma Network","startDate":"2019-09-23","conditions":"Light Chain (AL) Amyloidosis, Stage 3B","enrollment":40},{"nctId":"NCT04317872","phase":"NA","title":"Effect of Peri-operative Glucocorticoids on Short-term Functional Outcome After THA","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-07-01","conditions":"Coxarthrosis, Avascular Necrosis of Hip","enrollment":71},{"nctId":"NCT05635227","phase":"NA","title":"Dexamethasone, Olanzapine, Hemodynamics, and Ventilation in Cardiac Surgery","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2022-11-10","conditions":"Coronary Artery Disease, Aortic Valve Disease","enrollment":1200},{"nctId":"NCT06484829","phase":"PHASE1, PHASE2","title":"Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Chengdu Zenitar Biomedical Technology Co., Ltd","startDate":"2024-03-25","conditions":"Relapsed or Refractory Multiple Myeloma (RRMM)","enrollment":144},{"nctId":"NCT05707156","phase":"","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-07-05","conditions":"Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis","enrollment":12032},{"nctId":"NCT04392037","phase":"PHASE2","title":"Iberdomide Combined With Low-dose Cyclophosphamide and Dexamethasone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2021-02-17","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT04576689","phase":"PHASE2","title":"Safety and Efficacy of IBE-814 Intravitreal (IVT) Implant - a Sustained, Low Dose Dexamethasone Therapy","status":"COMPLETED","sponsor":"Ripple Therapeutics Pty Ltd","startDate":"2020-10-30","conditions":"Diabetic Macular Oedema, Retinal Vein Occlusion with Macular Oedema","enrollment":60},{"nctId":"NCT04895592","phase":"EARLY_PHASE1","title":"Radiosurgery Before Surgery for the Treatment of Brain Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-07-20","conditions":"Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm","enrollment":26},{"nctId":"NCT02649790","phase":"PHASE1, PHASE2","title":"Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications","status":"COMPLETED","sponsor":"Karyopharm Therapeutics Inc","startDate":"2016-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":277},{"nctId":"NCT05401812","phase":"PHASE2","title":"Glucocorticoid Therapy for Acute Respiratory Distress Syndrome","status":"WITHDRAWN","sponsor":"National Taiwan University Hospital","startDate":"2022-07-01","conditions":"Acute Respiratory Distress Syndrome","enrollment":""},{"nctId":"NCT01997840","phase":"PHASE1, PHASE2","title":"ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2014-03-01","conditions":"Multiple Myeloma","enrollment":103},{"nctId":"NCT06823934","phase":"NA","title":"Evaluation of the Effects of A-Prf and Oral Dexamethasone Use in Third Molar Extraction","status":"COMPLETED","sponsor":"Yuzuncu Yil University","startDate":"2021-10-04","conditions":"Wisdom Tooth Removal","enrollment":30},{"nctId":"NCT06818617","phase":"NA","title":"Analysis of Changes in Blood Glucose Spinal Epidural Nerve Block with Steroids in Patients with Low Back Pain","status":"NOT_YET_RECRUITING","sponsor":"Sung Hyun Lee","startDate":"2025-02-19","conditions":"Glucose Level Change","enrollment":60},{"nctId":"NCT05895838","phase":"PHASE3","title":"The Danish Out-of-Hospital Cardiac Arrest Study","status":"RECRUITING","sponsor":"Christian Hassager","startDate":"2023-06-16","conditions":"Out-Of-Hospital Cardiac Arrest, Post-Cardiac Arrest Syndrome","enrollment":1000},{"nctId":"NCT06536491","phase":"PHASE1, PHASE2","title":"EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema","status":"RECRUITING","sponsor":"Eclipse Life Sciences, Inc.","startDate":"2024-08-19","conditions":"Diabetic Macular Edema","enrollment":75},{"nctId":"NCT02990338","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-22","conditions":"Plasma Cell Myeloma","enrollment":307},{"nctId":"NCT03773107","phase":"PHASE1, PHASE2","title":"LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-01-03","conditions":"Multiple Myeloma","enrollment":12},{"nctId":"NCT03715478","phase":"PHASE1, PHASE2","title":"Multi-Center Study of GSK2857916 in Combination With Pomalidomide and Dex","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Myeloma Research Group","startDate":"2018-11-26","conditions":"Relapsed and/or Refractory Multiple Myeloma","enrollment":120},{"nctId":"NCT01903811","phase":"PHASE2","title":"S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2013-10","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":143},{"nctId":"NCT05665140","phase":"PHASE2, PHASE3","title":"Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients","status":"RECRUITING","sponsor":"University Hopsital Schleswig Holstein Campus Lübeck","startDate":"2023-02-03","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":100},{"nctId":"NCT06588413","phase":"PHASE3","title":"Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-09-17","conditions":"Multiple Myeloma, Autologous Stem Cell Transplantation","enrollment":172},{"nctId":"NCT02057380","phase":"PHASE2","title":"A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-04-16","conditions":"Advanced Solid Tumors","enrollment":13},{"nctId":"NCT00482261","phase":"PHASE2","title":"A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression","status":"COMPLETED","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2007-06","conditions":"Multiple Myeloma","enrollment":150},{"nctId":"NCT01093196","phase":"PHASE3","title":"Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Fondazione EMN Italy Onlus","startDate":"2009-10","conditions":"Multiple Myeloma","enrollment":660},{"nctId":"NCT02616640","phase":"PHASE1","title":"A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-01-11","conditions":"Multiple Myeloma","enrollment":114},{"nctId":"NCT05139043","phase":"PHASE2","title":"Low Dose Versus Standard Dose Dexamethasone for Reduction of Swelling in Patients with Primary or Metastatic Brain Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2022-04-09","conditions":"Malignant Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Malignant Brain Neoplasm","enrollment":26},{"nctId":"NCT03809442","phase":"PHASE4","title":"Analgesic Efficacy of Ropivacaine Alone or in Combination With Adjuvants on Post-operative Analgesia Following Video-Assisted Thoracoscopic Surgery.","status":"COMPLETED","sponsor":"Aga Khan University","startDate":"2019-06-25","conditions":"Postoperative Analgesia","enrollment":116},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06126354","phase":"PHASE1","title":"Dexamethasone/Pancreatic Clamp P&F","status":"WITHDRAWN","sponsor":"Columbia University","startDate":"2024-07-01","conditions":"Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease","enrollment":""},{"nctId":"NCT02400242","phase":"PHASE1","title":"Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma","status":"TERMINATED","sponsor":"Celgene","startDate":"2015-05-07","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT03010202","phase":"PHASE3","title":"The PROLONG Trial - Rituximab Maintenance Therapy in ITP","status":"UNKNOWN","sponsor":"Ostfold Hospital Trust","startDate":"2016-12","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":136},{"nctId":"NCT02770807","phase":"PHASE3","title":"Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients","status":"COMPLETED","sponsor":"Quince Therapeutics S.p.A.","startDate":"2017-03-02","conditions":"Nervous System Disease, Genetic Syndrome","enrollment":176},{"nctId":"NCT03517098","phase":"NA","title":"Enhanced Recovery After Surgery (ERAS) Pathway for Primary Hip and Knee Arthroplasty","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2021-02-01","conditions":"Arthroplasty, Replacement, Hip, Knee","enrollment":640},{"nctId":"NCT06336395","phase":"PHASE2","title":"Ma-Spore ALL 2020 Study","status":"RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2020-03-04","conditions":"B Lymphoblastic Leukemia","enrollment":500},{"nctId":"NCT00381680","phase":"PHASE3","title":"Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia","enrollment":275},{"nctId":"NCT05641324","phase":"PHASE1","title":"A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)","status":"TERMINATED","sponsor":"Anaveon AG","startDate":"2023-02-10","conditions":"Multiple Myeloma, Relapsed Cancer, Refractory Multiple Myeloma","enrollment":4},{"nctId":"NCT01858922","phase":"PHASE2","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2012-12-19","conditions":"Hodgkin Disease","enrollment":40},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT06175702","phase":"","title":"Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2023-12-25","conditions":"Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL","enrollment":150},{"nctId":"NCT03237611","phase":"PHASE2","title":"Low Dose Aprepitant for Patients Receiving Carboplatin","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2018-10-30","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":15},{"nctId":"NCT06111625","phase":"PHASE2","title":"Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2023-09-10","conditions":"Leukemia, Lymphoid","enrollment":20},{"nctId":"NCT02659800","phase":"PHASE1","title":"Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-10-30","conditions":"Lymphopenia, Malignant Glioma","enrollment":12},{"nctId":"NCT03877549","phase":"PHASE4","title":"Dexamethasone Administered Via the Epidural Catheter as an Adjunct in Patients Undergoing Cesarean Delivery","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2019-05-24","conditions":"Post Operative Pain","enrollment":""},{"nctId":"NCT04536363","phase":"PHASE2","title":"Cri Analog PG1 Effectiveness and Safety in Covid-19","status":"WITHDRAWN","sponsor":"Alonso Vera Torres","startDate":"2020-12-03","conditions":"Covid19","enrollment":""},{"nctId":"NCT04841018","phase":"NA","title":"Does Low Dose of Dexamethasone Enhance Analgesic Quality of Caudal Analgesia in Children Undergoing Orchiopexy?","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2021-03-24","conditions":"Patients With Cryptorchism Who Are Planning to Undergo Orchiopexy","enrollment":273},{"nctId":"NCT01346787","phase":"PHASE2","title":"Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients","status":"COMPLETED","sponsor":"European Myeloma Network B.V.","startDate":"2011-07","conditions":"Multiple Myeloma","enrollment":58},{"nctId":"NCT00101101","phase":"PHASE2","title":"Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2004-07","conditions":"Lymphoma","enrollment":43},{"nctId":"NCT03215524","phase":"PHASE2","title":"A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide","status":"COMPLETED","sponsor":"Canadian Myeloma Research Group","startDate":"2017-10-25","conditions":"Multiple Myeloma","enrollment":120},{"nctId":"NCT04561180","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia","status":"WITHDRAWN","sponsor":"Evergreen Therapeutics, Inc.","startDate":"2022-03-04","conditions":"COVID-19 Pneumonia","enrollment":""},{"nctId":"NCT04756128","phase":"PHASE2","title":"Impact of Colchicine and Low-dose Naltrexone on COVID-19","status":"COMPLETED","sponsor":"HealthPartners Institute","startDate":"2021-01-25","conditions":"Covid19","enrollment":142},{"nctId":"NCT05932524","phase":"PHASE2","title":"Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-07-07","conditions":"Immune Thrombocytopenia","enrollment":132},{"nctId":"NCT03809780","phase":"PHASE2","title":"Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone","status":"UNKNOWN","sponsor":"Kosin University Gospel Hospital","startDate":"2019-03-11","conditions":"Multiple Myeloma","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2267,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Dexamethasone low dose","genericName":"Dexamethasone low dose","companyName":"Manuel Taboada Muñiz","companyId":"manuel-taboada-mu-iz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dexamethasone is a synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in the cytoplasm. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, systemic lupus erythematosus), Adrenocortical insufficiency, Cerebral edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}